In our previous studies, decreased FOXF2 expression was associated with early-onset metastasis and poor prognosis for patients with triple-negative breast cancer [12], and further studies showed that FOXF2 can inhibit epithelial-mesenchymal transition (EMT) and metastasis of basal-like breast cancer by targeting TWIST1 [13] and FOXC2 [14] directly. The gene discussed is FOXF2; the disease is breast cancer.